Bristol Myers Squibb (NYSE:BMY – Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $1.53 per share and revenue of $11.32 billion for the quarter.
Bristol Myers Squibb Trading Down 1.4%
Bristol Myers Squibb stock opened at $46.85 on Wednesday. The stock has a market cap of $95.35 billion, a P/E ratio of 17.55, a PEG ratio of 2.50 and a beta of 0.36. Bristol Myers Squibb has a fifty-two week low of $44.00 and a fifty-two week high of $63.33. The firm’s fifty day moving average price is $47.65 and its 200-day moving average price is $52.49. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28.
Bristol Myers Squibb Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. Bristol Myers Squibb’s payout ratio is currently 92.88%.
Analyst Ratings Changes
Read Our Latest Stock Report on Bristol Myers Squibb
Institutional Trading of Bristol Myers Squibb
An institutional investor recently raised its position in Bristol Myers Squibb stock. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 33.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,728 shares of the biopharmaceutical company’s stock after purchasing an additional 4,935 shares during the period. Brighton Jones LLC’s holdings in Bristol Myers Squibb were worth $1,116,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- What is the FTSE 100 index?
- Should Investors Lock Arms With Buffett and Dive Into POOL Stock?
- What Does Downgrade Mean in Investing?
- Big 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2
- About the Markup Calculator
- Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.